V.Med BAM15 & SLU-PP

This formulation combines two cutting edge compounds BAM15 and SLU-PP to support metabolic enhancement energy expenditure and fat reduction. BAM15 is a mitochondrial uncoupler studied in rodent models to increase nutrient oxidation reduce body fat mass improve insulin sensitivity and reduce liver fat without reducing food intake or lean mass. PMC SLU-PP (also called SLU-PP-332) is an ERR (Estrogen Related Receptor) agonist that mimics many of the metabolic benefits of exercise by increasing mitochondrial function enhancing fatty acid oxidation and improving endurance capacity and metabolic flexibility. University of Florida News+2Journal of Renal Endocrinology+2

Properties & Effects

• Elevated basal metabolic rate due to mitochondrial uncoupling via BAM15 which increases calorie burn even at rest
• Enhanced lipid metabolism driven by SLU-PP leading to greater fat oxidation and reduced fat accumulation especially in adipose tissue and liver
• Improved insulin sensitivity and glucose homeostasis supported by both compounds working via different but complementary pathways
• Increased energy output endurance and possibly mitochondrial density which may lead to improved performance during workouts or extended metabolic stress
• Potential antioxidant and anti-inflammatory effects especially in liver tissue with reduction of oxidative stress markers when using BAM15 in animal studies PMC

Mechanism of Action

BAM15 acts by reducing mitochondrial coupling efficiency allowing the body to consume more substrates (fats and other nutrients) to produce the same amount of ATP this causes increased energy expenditure and fat oxidation without forcing a higher food intake. PMC SLU-PP binds to and activates estrogen related receptors ERRα ERRβ and ERRγ in muscle liver and other tissues those receptors regulate genes involved in mitochondrial biogenesis oxidative phosphorylation fatty acid metabolism and energy usage during periods of metabolic demand or exercise mimic conditions. Activating ERRs increases mitochondrial respiration PDK4 expression and supports enhanced endurance performance. Journal of Renal Endocrinology+2RegenMD+2

Recommended Use

Use this product under a carefully controlled protocol start with a low dose to assess tolerance then apply the full tablet dosage daily as indicated or split dose if needed depending on individual response. Given this is a combination tablet with strong mitochondrial and metabolic actions begin with intermittent use for example 5-7 days on followed by short break to assess effect and avoid overtaxing metabolic systems. Combine with a clean diet sufficient protein hydration and moderate cardio resistance work to amplify effects. Monitoring of metabolic markers glucose lipids liver function is advised.

Safety & Side Effects

Both compounds are experimental research agents their safety in humans has not been established. Possible side effects include increased metabolic strain fatigue or discomfort particularly in early phase of use as the body adjusts to higher energy turnover. Gastrointestinal disturbances could occur. Overuse or too high dosage may stress mitochondria induce oxidative stress or affect liver function. Avoid in cases of pre-existing liver disease mitochondrial disorders or if pregnant or breastfeeding. Always obtain from reliable source ensure purity and dosage accuracy.

Special Notes

Effects of this combo are cumulative improvements may take several weeks to become noticeable especially for changes in body composition and endurance. Exposure to very high heat extreme conditions or improper storage may degrade SLU-PP potency. This product is not evaluated by regulatory authorities as treatment for any disease. Not intended for persons under medical supervision where such supervision is required.